Feasibility, limits and problems of clinical studies in Intensive Care Unit by G. Grasselli et al.
Vol. 73 - No. 11 MINERVA ANESTESIOLOGICA 595
MINERVA ANESTESIOL 2007;73:595-601
R E V I E W A R T I C L E
Feasibility, limits and problems of clinical studies in
Intensive Care Unit 
G. GRASSELLI 1, L. GATTINONI 2, B. KAVANAGH 3, R. LATINI 4, A. LAUPACIS 5, F. LEMAIRE 6,
A. PESENTI 2, P. SUTER 7, A. SLUTSKY 8, G. TOGNONI 9
1De p a rtment of Pe r i o p e r a t i ve Medicine and In t e n s i ve Care, San Ge r a rdo Hospital, Un i versity Milano Bicocca, Mi l a n ,
Italy; 2De p a rtment of Anesthesia and In t e n s i ve Care, IRCCS Foundation, “ Ma g g i o re Policlinico, Mangiagalli, Re g i n a
El e n a” Hospital, Un i versity of Milan, Milan, Italy; 3De p a rtment of Anesthesiology and Critical Care Medicine,  Ho s p i t a l
for Sick Children, Un i versity of To ronto, To ronto Canada; 4De p a rtment of Card i ovascular Re s e a rch, Mario Negri In s t i t u t e ,
Milan, It a l y, 5Li Ka Shing Knowledge Institute, To ronto, Canada; 6Assistance Publique-Hôpitaux de Paris, H. Mo n d o r
Hospital, Un i versity Paris XII, Créteil, France; 7Un i versity of Ge n e va, Ge n e va, Sw i t zerland; 8Division of Re s p i r a t o ry
Medicine,  St. Mi c h a e l’s Hospital, Un i versity of To ronto, To ronto, Canada; 9C o n s o rzio Mario Negri Sud, Santa Ma r i a
Im b a ro, Chieti, It a l y
A B S T R A C T
In critical care medicine there is still a paucity of evidence on how to manage most of the clinical problems common-
ly encountered in critically ill patients. Randomized controlled trials (RC Ts) are the most powe rful instruments to
e valuate the efficacy of a therapeutic intervention and to generate evidence for clinical practice. Un f o rt u n a t e l y, the
design and conduct of RCTs in our field are particularly complicated, because of some intrinsic and structural prob-
lems (e . g . lack of reliable nosography, concomitant use of different therapies, problems in the definition of end-points
besides mortality) that will be discussed in this re v i ew. Fu rther challenges are re p resented by the lack of tradition of large
ICU networks, difficulties in linking or integrating physiologic and therapeutic objectives in designing clinical pro-
tocols, scarcity of independent or non-profit funds. A particularly stimulating opportunity of development is repre-
sented also by the relationship of critical care to EBM. Because of the above problems, metanalyses could be less
i n f o r m a t i ve than in other areas of medicine, as they are based on few trials which are often contradictory and of unsat-
isfactory quality. Few suggestions are formulated which could help looking forwards. 
Key words: Randomized controlled trial - Evidence-based medicine - Data interpretation, statistical - Mortality.
The process of a clinical trial
Clinical trials are today re c o g n i zed as the pre-f e r red, and somehow mandatory tool, to pro-
duce an information on drugs and/or strategies of
i n t e rvention which could be considered sufficient-
ly reliable to guide routine care. T h e re is now a
b road agreement on the criteria and conditions for
the planning and execution of physiologic as we l l
as of therapeutic trials, which can be summarize d
in the following points, where the main stre n g t h s
as well as weaknesses are underlined.
1. Mo t i vation(s) and feasibility. The scenarios are
many: 
a. the need to define whether and how an “inter-
ve n t i o n” (not necessarily centered on a drug) pro-
duces effects which correspond to a we l l - p re d e-
fined hypothesis leads to “p h y s i o l o g i c” trials, which
a l l ow a more thorough understanding of the inter-
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play of the variables and/or indicators/markers of
a clinical condition and of its evolution;
b. a therapeutic trial aims to assess the existence,
the direction, the size, the clinical and statistical sig-
nificance of an intervention on the morbidity-
mortality of a target population; 
c. a limited number of well defined and care f u l-
ly monitored patients is usually re q u i red for phys-
iologic studies; much larger populations re p re s e n-
t a t i ves of the real conditions of care are needed to test
the efficacy (and the associated safety) of an inter-
vention on clinical (and/or epidemiological) out-
comes of re l e vant morbidities and mortality; 
d. the combination of the two approaches would
be obviously more informative, but it is rare l y
planned and implemented, for logistics, financial,
but mainly motivational reasons of the promoters; 
e. it is increasingly re c o g n i zed that in many
instances the motivations for a trial reflect more a
pressure from the market (mainly for therapeutic
trials).
2. Issue definition: this re q u i rements encom-
passes both the need for an explicit and univocal
definition of the condition to be treated, and of
the expected outcome(s) or result(s). The “labora-
t o ry - l i k e” approach requested for a physiologic
study is more compatible with the above require-
ments. Therapeutic trials on complex conditions,
such as those more specifically met in critical care ,
could be facing difficulties in the process of defi-
nition(s) (e . g . sepsis or acute re s p i r a t o ry distre s s
syndrome, ARDS).
3. Protocol design: a correct description of the
study design, of inclusion-exclusion criteria and
of re q u i red sample size is of cornerstone impor-
tance. Ethical issues (informed consent) and iden-
tification of the type and number of part i c i p a t i n g
units also deserve special attention.
4. Analysis of results: statistical methods must
be rigorous and appropriate. 
5. Publication: the site, or journal, is of utmost
i m p o rtance “Top journals” are obviously pre f e r re d
for important positive or negative results, though
sometimes reasons other than strict scientific qual-
ity determine the accessibility to “top journals” ,
and there f o re the potential impact of the re s u l t s
on medical practice. 
Clinical trials in the intensive care unit: 
peculiarities and special issues
The process of planning and implementing tri-
als according to the above steps is certainly more
likely to be not easy in many conditions of critical
c a re, because of their baseline complexity, va r i-
a b i l i t y, difficult definition(s), coexistence of many
not easily standard i zed management strategies.
The following considerations underline some of the
main issues.
1. ICU are dealing more with syndromes than
with well defined diseases. The diagnostic and
p rognostic definition of these syndromes is some-
times ve ry difficult because it is based on nonspe-
cific and nonselective criteria that are often a mat-
ter of debate. For example, diagnostic criteria for
ARDS are extremely broad and nonspecific 1 a n d
encompass several clinical situations that are clear-
ly unrelated to each other.2 The inclusion criteria
define there f o re inevitably populations which are
expected to reflect important variabilities, which
are likely not to be perfectly matched by the ran-
domization process: higher “n u m b e r s” a re desir-
able, but they imply very broad networks, where
practices could howe ver contribute further va r i-
ability due to the sometimes different and not eas-
ily comparable management strategies.
2. Type of intervention: therapeutic interven-
tions in the ICU are in general much more com-
plicated than in other settings and are quite differ-
ent from the simple administration of a new dru g .
In critical care we test interventions that are com-
plex, re q u i re a re l a t i vely long learning time and
sometimes are not well defined. In addition, the
patients receive many concomitant therapies and
this makes the evaluation of the effect of a single
i n t e rvention quite difficult: in other words, it can
be hard to distinguish the direct effect of the exper-
imental treatment from the composite effect of all
concurrent therapies. A corollary of this observa-
tion is that for many of the clinical conditions we
h a ve to face we do not have a “s t a n d a rd tre a t m e n t”
to be used as control. A clear example of this is
the ARDSnet trial, that compared the effect of
two different tidal volumes (12 mL/kg, pre d i c t e d
body weight as standard treatment vs 6 mL/kg, as
the experimental arm) in patients with ARDS.5
The trial unequivocally demonstrated that using
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a tidal volume of 6 mL/kg is better than using the
higher tidal volume in terms of overall surv i va l .
But can we affirm without doubt that a tidal vol-
ume of 12 mL/kg really re p resented standard tre a t-
ment?6, 7
3. Outcome indicators: in ICU we treat con-
ditions associated with very high mortality rates.
This obviously makes mortality an important out-
come (maybe the most important one) but poten-
tially very hard to improve, so that large number
of patients are re q u i red to demonstrate a significant
s u rv i val advantage. To date, only a ve ry limited
number of the therapies used in critical care med-
icine have been proved to significantly reduce mor-
tality. The lack of a clear impact on mortality has
caused the rejection of several promising new ther-
apies in the last decade. As pointed out by Petros
et al. in 1995, the use of mortality as a primary
endpoint in ICU-based trials is associated with
some problems.8 Besides the importance of large
number of patients, two lines of methodological
solutions could be possibly adopted. 
The use of attributable mortality instead of all-
cause mortality would be desirable, since it may
a l l ow a reduction of the sample size. To under-
stand this concept, we can consider the patients
with ARDS: overall mortality is 40% and mort a l-
ity attributable to ventilator-induced lung injury
(VILI) can be estimated around 10%. Let’s imag-
ine that we want to test a new ve n t i l a t o ry strategy
that halves VILI-induced mortality: to demon-
strate a drop in overall mortality from 40% to
35% we have to enrol 1 471 patients, whereas to
s h ow a reduction in VILI-attributable mort a l i t y
from 10% to 5% the required sample size would
be only of 435 subjects. Un f o rt u n a t e l y, determin-
ing the attributable mortality can be difficult.  
Though the use of different prognostic severi-
ty scores (APACHE, SAPS, ect.), and/or indicators
of morbidity may be imprecise and misleading:
an intelligent (and clearly pre-defined in terms of
reliability and qualified re l e vance) adoption of sur-
rogate and/or intermediate endpoints (instead of,
or cumulative with mortality) could be explored
and encouraged. For example, when testing a new
ve n t i l a t o ry strategy, measures of its physiologic
effect (such as gas exchanges or lung mechanics) or
measures of morbidity (such as the rate of infec-
tions or duration of mechanical ventilation) may
be more relevant endpoints than overall mortali-
ty.
The problem of evidence-based medicine and
statistical considerations
Evidence-based medicine (EBM) can be defined
as the application of the best evidence from re s e a rc h
to clinical practice. The concept of EBM was first
p roposed in 1992;9 since then, it has become
i n c reasingly popular and there are now many ded-
icated journals and more than 30 websites.
The basic principle of EBM is that clinical prac-
tice should be based on the results of published
t r i a l s .1 0 In the attempt to define “the best evidence
f rom re s e a rc h”, a hierarchy of the possible sourc e s
has been established. RCTs are judged to provide
the best possible evidence, followed by meta-analy-
ses, case-control and case-series studies.1 1
Ap p ropriately sized and high quality RC Ts are the
most powe rful tool, but this does not mean that the
results of a single RCT should be passively accept-
ed and become a new standard of care .1 2 Ma n y
questions are still open and RC Ts on the same
subject often give conflicting results. A number
of issues must be addressed: is the sample size ade-
quate, are enrolment criteria and statistical meth-
ods stringent enough to allow the extrapolation
of results to the general population, and are the
results generalizable.13
We are dealing with inferential statistics, which
is the art of using samples to reach conclusions (of
specific reliability) about populations. With re s p e c t
to this problem, some points should be highlight-
ed. By convention, a difference between groups is
usually re p o rted as statistically significant if the P
value is 0.05 or less: this means that the pro b a b i l-
ity that the findings are due to chance is less than
5% (1/20). T h e re is considerable debate among
statisticians and epidemiologists on the impor-
tance of the P va l u e :12, 14, 15 this figure is in fact
heavily dependent on sample size and may not
g i ve any information about the actual clinical re l-
evance of the results. In an editorial published in
1968 in the New England Jo u rnal of Me d i c i n e i t
was stated: “ Significant, being one of the words that
mean eve rything or nothing, is too convenient for the
MINERVA MEDICA COPYRIGHT®
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medical writer (...). In its vulgar sense, unrelated to
statistical manipulations, it comfortably serves ambi -
guity (...). It permits an author to describe his find -
ings as significant (...) without requiring him to use
an acceptable measure of that importance”.15
According to Altman and Bland, the interpre-
tation of non significant findings (P > 0.05) may
be particularly misleading: lack of significance
does not mean that there is no difference betwe e n
g roups, but only that there is no evidence of a dif-
f e re n c e .1 6 In other words, the P value is just an
acceptable level of the risk of being wrong.
When we observe a difference between tre a t-
ment and control arms that may be clinically rel-
e vant but does not achieve statistical significance,
t h e re is the risk of rejecting a potentially useful
t h e r a p y. In this case we have two options: the first
is to decrease data dispersion by increasing sample
s i ze; the second (lazier) option, is to pool the data
with other similar trials (i . e . meta-analysis). In
highly selected situations, it may be possible to
use a one-tail test instead of the usual two-tail test.
The use of two-tail test is not a dogma. A one-tail
test can be considered whenever an effect can only
occur in one direction: an accepted indication is the
p reclinical screening of active molecules, when we
a re interested only in picking up effective com-
pounds; other examples can be found in rare dis-
eases, that for some aspects can be compared to
ARDS. In the clinical setting the conditions for
the use of one-tail test are rarely met.  
As already stated, the level of significance (P
value) is arbitrary and does not tell us anything
about the clinical re l e vance of an observed differ-
ence or about cause-effect relationships. T h e s e
considerations are particularly re l e vant in the case
of very large RCTs, as shown in a recent paper by
Villar et al.12 It is well known that the most rele-
vant data to describe the clinical impact of a tre a t-
ment are the absolute risk reduction and the 95%
confidence interval (CI) for this difference. Another
i m p o rtant parameter is the number needed to tre a t
( N N T, calculated as 1/absolute risk re d u c t i o n ) ,
which describes the number of patients that need
to be treated to pre vent one adverse eve n t .
Unfortunately, in most clinical trials the NNT is
not re p o rted and the re l a t i ve risk reduction is used
instead of the absolute risk reduction: this may
lead the clinician to overestimate the efficacy of a
new treatment.12
Other problems arise from the widespread use
of subgroup analysis.1 7 - 1 9 In an attempt to improve
the prediction of the individual effect, investiga-
tors often analyze data from trials by subgro u p s
within which responses are expected to be simi-
lar but between which responses are suspected to
d i f f e r. Un f o rt u n a t e l y, the interpretation of re s u l t s
in subgroups is fraught with inferential pro b l e m s .
If for example we consider a trial comparing a
worthless treatment with a control and we divide
patients into 10 mutually exc l u s i ve subgroups, we
will have a 20% chance (P < 0.05) to conclude
that treatment is significantly better than control
in at least one subgro u p, but also a 20% chance to
obtain the opposite results. To avoid these pitfalls,
the statistical analysis plan must be clearly prede-
fined; subgroup findings should be exploratory
and only exceptionally used to affect a trial’s con-
clusions.19
Si m i l a r l y, the results of i n t e r i m analyses lead-
ing to pre m a t u re interruption of a trial can be par-
ticularly misleading and should be interpre t e d
with great caution. One of the roles of Data Sa f e t y
and Monitoring Boards (DSMB) is to care f u l l y
assess i n t e r i m to ensure the safety of part i c i p a t i n g
s u b j e c t s .2 0 O ver the past decade the use of DSMBs
has increased substantially, mainly due to the grow-
ing number of trials with mortality as the primary
end-point and to the greater awareness of poten-
tial biases that can result with early stopping a
s t u d y. The critical challenge is to determine when
i n t e r i m data can be considered reasonably conclu-
sive, thus justifying an early termination of a tri-
al because of evidence that one treatment has
g reater efficacy or causes greater harm than anoth-
e r. When interim data are analyzed multiple times,
the use of a P value of 0.05 or less as the stopping
criterion can lead to a false conclusion, due to the
effect of multiple tests of significance.2 1 Mo re ove r,
the results of clinical trials that are stopped early are
likely to exaggerate the magnitude of a treatment
e f f e c t .2 2 In a recent paper, Montori et al. e x a m i n g
a large number of trials pre m a t u rely stopped
s h owed that the percentage of trials that we re
stopped early increased from 0.5% in the ye a r s
1990-1994 to 1.2% in the interval 2000-2004,
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with an average accrual of 63% of planned sample
size.23
In the literature, there are some clear examples
of large trials that at the i n t e r i m analysis we re close
to being stopped because of a ve ry strong tre n d
favoring one treatment arm but that at the com-
pletion failed to show any significant differe n c e
between the 2 groups.20, 24, 25 To overcome these
p roblems statisticians have proposed a number of
rules for i n t e r i m analysis, a complete list of which
is beyond the scope of this paper. We believe that
the most reasonable approach is to use very strin-
gent stopping criteria, so that trials are terminat-
ed early only when there is clear evidence that a
t reatment is better than another: for example, Pe t o
et al. proposed that trials should be stopped only
if the P value is less than 0.001 at any i n t e r i m
analysis.26
Despite these considerations, there is no doubt
that RCTs are the gold standard in evaluation of
the efficacy of clinical interventions. When large
RC Ts are not available, clinicians usually take into
account meta-analyses as the preferred source of
evidence to guide their clinical behaviour. T h e
intrinsic strengths and weaknesses of meta-analy-
ses have been the subject of several re v i ews 27, 28
and will not be discussed here. Of note, the abil-
ity of meta-analyses to predict the results of RC Ts
on the same subject is quite limited.29 For exam-
ple, Le Lorier et al. c o m p a red the results of 12
RCTs and 19 meta-analyses addressing the same
questions and showed that the outcomes of the
RCTs were not predicted 35% of the time by the
meta-analyses previously published on the same
subject.30
Summarizing this section, we believe that the
use of EBM in the intensive care setting has been
a useful development, but unfortunately many
therapies have not been rigorously evaluated. We
need large and unbiased RC Ts to translate evi-
dence coming from research into current clinical
practice. Results from clinical trials must be inter-
p reted critically and combined with evidence fro m
other forms of research. EBM is not a “cookbook
m e d i c i n e” applicable in all situations, but rather a
clinical decision making process that relies on the
judicious use of results from clinical studies com-
bined with clinical experience, clinical re a s o n i n g ,
understanding of pathophysiology and of patients’
p re f e rences. It is particularly important to stre s s
the concept that EBM must not be viewed as an
attempt to denigrate clinical experience and clin-
ical intuition nor to de-emphasize the import a n c e
of understanding the physiopathologic mecha-
nisms of diseases.3 1 As stated by Bro c h a rd et al.
“physiological and clinical understanding are need-
ed as foundation stones before pillars of evidence
can be erected”.10
Importance of
physiological studies
From the previous discussion, the importance
of physiological studies should become evident.
Studies exploring physiological issues are needed
to increase our understanding of etiology and
pathophysiology of diseases. This should also help
to obtain more precise definitions of the syndro m e s
associated with critical illness.
A strong physiological rationale is necessary for
the design of meaningful clinical trials. In this
sense the role of physiological studies can be com-
p a red to that of phase I-II studies in the process of
d rug development: these studies provide informa-
tion on safety, dosage and spectrum of activity of
the experimental drug that are essential for the
design of phase III (randomized) trials.
For example, if the hypothesis behind the use of
higher positive end expiratory pre s s u re (PE E P )
l e vels is that it improves re c ruitment, a randomize d
trial exploring two different PEEP levels in ARDS
would have a greater chance of success if it was
possible to predict the potential for re c ru i t m e n t
in individual patients, an issue that can be
a d d ressed only exploring the physiological mech-
anisms of lung re c ruitment. By their nature, phys-
iological studies should be performed in specialize d
and selected units, whereas participation in RC Ts
a d d ressing clinical questions can be extended to
a larger number of ICUs.
Un f o rt u n a t e l y, physiological studies are
becoming more difficult to perform even in high-
ly specialized units, mainly due to economic and
ethical issues. As suggested above, to ove rc o m e
also these difficulties a promising strategy should
be their nesting in, and/or articulation with, ear-
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ly (phase II) or therapeutic (phase III and IV)
trials, so that their results could be more easily
linked and finalized to the understanding and/or
the better qualification of clinical-therapeutic
re s u l t s .
Conclusions
Critical care is a re l a t i vely young branch of med-
icine in continuous and rapid evolution. Many of
the therapeutic interventions in this field are still
waiting for a rigorous evaluation. The only way
to generate and increase our knowledge is re s e a rc h .
The most powerful research tools to evaluate the
efficacy of a therapeutic intervention are RC Ts .
In critical care, we need a cultural re volution to
consider RC Ts as the pre f e r red way of conduct-
ing clinical trials: they should become the ro u t i n e
rather than an exception. 
As discussed above, there are some intrinsic and
structural problems (lack of reliable nosography,
difficulties in identifying adequate control gro u p s ,
concomitant use of different therapies, use of mor-
tality as primary endpoint) that make the design
and conduct of RC Ts in our discipline part i c u l a r-
ly difficult. En rolment of large numbers of patients
is also hindered by the limited number of ICU
beds. These considerations partially explain why so
many clinical trials in our field give negative re s u l t s ,
i.e. they fail to demonstrate a statistically signifi-
cant difference between treated patients and con-
trols.  
Every effort should be done to overcome these
problems. In particular: 1) we need better defini-
tions of the common critical care syndromes (e.g.
sepsis, ARDS ...); 2) we also need to increase the
number of physiologic studies, to increase our
understanding of pathophysiology and etiology
of diseases; and 3) the creation of a large network ( s )
of re s e a rch ICUs (ideally with comparable leve l
of patient care) to carry out randomized clinical tri-
als is necessary to increase the enrolment of ade-
quate numbers of patients, such as occurs in the
oncology and cardiovascular setting.
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ice
s 
or
 te
rm
s 
o
f u
se
 w
hi
ch
 th
e 
Pu
bl
is
he
r m
ay
 p
os
t o
n 
th
e 
Ar
tic
le
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 fr
a
m
e
 o
r 
u
se
 fr
a
m
in
g 
te
ch
ni
qu
es
 to
 e
nc
lo
se
 a
ny
 tr
a
de
m
ar
k,
 lo
go
,
o
r 
o
th
er
 p
ro
pr
ie
ta
ry
 in
fo
rm
a
tio
n 
of
 th
e 
Pu
bl
is
he
r.
